News

An assessment of severe coronavirus patients administered either five-day or 10-day remdesivir treatment shows benefit is fairly similar, regardless of duration.

A new paper analyzed cancer types to determine which types of cancer put a patient at highest risk of contracting coronavirus.

A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.

The indication is based on positive findings from a pair of Africa- and Asia-based randomized trials.

Based on findings from a comparative-dose trial with a candidate vaccine, headway is being made in the process toward a MERS prophylaxis.

A daily news update on our COVID-19 coverage.

Helen W. Boucher, MD, FACP, FIDSA, discusses the need for a transparent distribution process for remdesivir, plus COVID disparities, secondary infections, and what “the new normal” of health care looks like.

The novel drug combines a fourth-generation cephalosporin with a novel extended-spectrum β-lactamase inhibitor.

Clinicians should be wary of risk for depression, anxiety, fatigue, PTSD, and, potentially, rare neuropsychiatric syndromes, in post-coronavirus patients.

While not without its challenges, converting a pediatric intensive care unit to care for adult novel coronavirus patients was the right decision for the Mass General Hospital for Children.

Executive members of coronavirus therapy candidate global assessment came to decision after new data showed the therapy was linked to increased mortality and cardiovascular event risk.

Drug resistance has physicians racing to find alternative therapies for many infections. In a new non-inferiority study, fosfomycin was inferior to more common therapies.

Preliminary results were highly anticipated, given Anthony Fauci, MD, made optimistic statements about the drug in late April.

A weekly recall round-up.

An analysis by health officials in the UK shows patients in the community (as opposed to the hospital) who were tested for coronavirus had the highest rate of positive results.

Gram-negative bacteria can cause infections, are resistant to multiple drugs, and are increasingly resistant to most available antibiotics, the CDC says.

A brief summary of the latest infectious disease news.

Vickie Mays, PhD, uses her training in clinical psychology to provide insight on the long-term cognitive impact of the coronavirus pandemic and outbreak response.

The financial support will ensure AstraZeneca will develop at least 400 million doses, with plans to begin distribution in September.

Saskia v. Popescu, PhD, MPH, MA, CIC, discusses vaccine development, fighting COVID misinformation, and lessons learned from the pandemic.

Adding thromboelastogram to D-dimer measure could enable early ID of patients who require aggressive anticoagulation for severe COVID-19.

There may be more fatalities linked to COVID-19 in Los Angeles County than previously thought.

An update on our daily coverage.

COVID-19 places the physical and mental health of healthcare workers at risk—and it’s time to take action.

The vaccine candidate demonstrated neutralizing antibody and T cell immune response against the novel coronavirus.

Two patient case series suggest pronation could improve oxygenation with non-invasive ventilation in some patients with coronavirus.

Investigators compare infection rates among heathcare workers throughout different coronavirus epidemics, including SARS, COVID-19, and MERS.

The largest US prospective study of patients to date shows most COVID-19 patients in the ICU are older, minorities, have underlying cardiometabolic disease—and are highly likely to require mechanical ventilation.